Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
Päätekijät: | Lee, M, Beeson, D, Palace, J |
---|---|
Aineistotyyppi: | Journal article |
Kieli: | English |
Julkaistu: |
Wiley
2018
|
Samankaltaisia teoksia
-
The congenital myasthenic syndromes.
Tekijä: Palace, J, et al.
Julkaistu: (2008) -
Congenital myasthenic syndromes.
Tekijä: Beeson, D, et al.
Julkaistu: (1997) -
Congenital myasthenic syndromes: an update.
Tekijä: Finlayson, S, et al.
Julkaistu: (2013) -
Congenital myasthenic syndromes and the neuromuscular junction.
Tekijä: Cruz, P, et al.
Julkaistu: (2014) -
The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes
Tekijä: Rodríguez Cruz, P, et al.
Julkaistu: (2018)